Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is well-positioned for future success due to their strong clinical-stage assets and strategic focus on leveraging individual's neurobiology for personalized treatment options. With a solid cash runway through 2029, the company remains well-funded to continue their research and development efforts. Although delays in timing for some of their key pipeline updates may be disappointing, they do not impact the overall potential of their portfolio and current valuation of $24 per share is in line with our target.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company that focuses on developing personalized treatments for psychiatric disorders. However, the company carries a high level of risk due to its early stage developmental programs and unproven biomarker approach. With a low probability of success for its drug candidates and potential challenges in commercializing its products, we maintain a negative outlook on Alto Neuroscience's stock.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.